Evonik Take Complete Control of Carbon Black Joint Venture

Evonik Industries has acquired the remaining 50percent shares in its former carbon black Joint Venture Degussa Engineered Carbons (DEC) effectively October 29, 2007 from ECI. DEC will now be a 100percent owned subsidiary of Evonik. Financial details of the transaction will not be disclosed. Closing has occurred.

“Carbon black is one of our strategic growth areas that we are systematically expanding. This transaction underlines Evonik’s commitment in the North American market and will add significant value to our Group,” said Dr. Klaus Engel, Member of the Management Board of Evonik and responsible for the Chemicals business area. Thomas Hermann, head of Evonik’s Advanced Fillers & Pigments Business Unit, commented: “The acquisition is an important step to consolidate our position in one of our key strategic markets, and will help us to serve our global key accounts even better.”

In 2002 Evonik and ECI formed the joint venture to combine their carbon black businesses in North America. DEC is headquartered in Parsippany, New Jersey/U.S., and produces and markets furnace grade carbon blacks for the rubber and pigment industries in North America and thermal blacks worldwide.

DEC is one of the activities of Evonik’s Business Unit Advanced Fillers & Pigments which is present globally in 30 production locations in 18 countries on five continents. Evonik is the only one-stop-shop supplier of carbon black, rubber silicas and rubber silanes. This makes the Advanced Fillers & Pigments Business Unit one of the highest performing system providers for the rubber-processing industry. The business unit’s entire product range also offers tailor-made solutions to manufacturers of dyes, enamels, and printing inks, and to the plastics industry.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.